EpiAirwayTM Technical References
456. |
NEW! |
AN IN VITRO MODEL OF HUMAN AIRWAY EPITHELIUM (EPIAIRWAY™) FOR IN VITRO METABOLISM, TOXICITY SCREENING AND DRUG DELIVERY APPLICATIONS.
Bolmarcich, J., Stolper, G., Jackson, G.R., Klausner, M., Hayden, P.J.
MatTek Corporation, Ashland, MA.
Presented at 6th World Congress on Alternatives and Animal Use, Tokyo, August (2007).
|
448. |
NEW! |
IN VITRO AND IN VIVO SCREENING OF INTRANASAL INSULIN FORMULATIONS.
Cohen, A.S., Sileno, A.P., Peddakota, L.R., Forseth, K.T., Slater, A., Haugaard, D., Foerder, C.A., Brandt, G.C., Quay, S.C., and Costantino, H.R.
Nastech Pharmaceuticals, Bothell, WA.
Presented at the American Association of Pharmaceutical Scientists (AAPS) Biotechnology Conference, Boston, MA, June 18-21, (2006).
|
447. |
NEW! |
SYSTEMATIC IDENTIFICATION OF PROTEASES AND ANTI-PROTEASES IN DEVELOPING PRIMARY AIRWAY EPITHELIAL CELLS BY GLOBAL GENE EXPRESSION.
Moffatt1, M.F., Taylor1, J., Hao1, L., Hayden2, P.J., Cookson1, W.O.
1Oxford University, Oxford, England, 2MatTek Corp., Ashland, MA (USA).
Presented at the American Thoracic Society Annual Meeting, San Francisco, CA, May 22, Poster No. D17 (2007).
|
446. |
NEW! |
CYTOKINE-INDUCED GOBLET CELL HYPERPLASIA IN THE (EPIAIRWAY-FT) IN VITRO FULL-THICKNESS HUMAN AIRWAY MODEL.
Hayden, P.J., Jackson, G.R., Bolmarcich, J.L., Stolper, G., Spiller, E. and Klausner, M.
MatTek Corporation, Ashland, MA, United States.
Presented at the American Thoracic Society Annual Meeting, San Francisco, CA, May 22, Poster No. B33 (2007).
|
445. |
NEW! |
DNA DOUBLE-STRAND BREAKS FORM IN BYSTANDER CELLS AFTER MICROBEAM IRRADIATION OF THREE-DIMENSIONAL HUMAN TISSUE MODELS.
Sedelnikova1, O.A., Nakamura1, A., Kovalchuk2, O., Koturbash2, I., Mitchell3, Marino3, S.A., Brenner3, D.J., and Bonner1, W.M.
1Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland; 2Department of Biological Sciences, University of Lethbridge, Lethbridge, Alberta, Canada; and 3Radiological Research Accelerator Facility, Center for Radiological Research, College of Physicians and Surgeons, Columbia University, New York, New York.
Cancer Res 2007, 67, (9), 4295-302, (2007)
|
428. |
NEW! |
CHARACTERISATION OF AIRBORNE PARTICULATE MATTER AND RELATED MECHANISMS OF TOXICITY: AN EXPERIMENTAL APPROACH.
Bérubé1, K., Balharry1, D., Jones1, T., Moreno2, T., Hayden3, P., Sexton1, K., Hicks1, M., Merolla1, L., Timblin4, C., Shukla4, A., Mossman4, B.
1Cardiff University, Cardiff, United Kingdom, 2Institute of Earth Sciences Jaume Almera, Barcelona, Spain, 3MatTek Corporation, Ashland, MA, 4University of Vermont, Burlington, Vermont.
Published in Air Pollution and Health. Editor: Maynard, R.L. Imperial College Press, London, United Kingdom, 69-110 (2006). ISBN# 1-86094-191-5.
|
415. |
NEW! |
PEPTIDES AND PEGYLATED PEPTIDES AS INTRANASAL PERMEATION ENHANCERS: COMPARISON TO SMALL MOLECULAR EXCIPIENTS.
Lamharzi, N., Sileno, T., Eiting, K.T., Templin, M., Haugaard, K.D., Houston, M., Cui, K., Johnson, P.H., Chen, S-C.
Nastech Pharmaceutical Company, Inc., Bothell, Washington.
Journal of Pharmaceutical Sciences, 95, (6) 1364-1371 (2006).
|
414. |
NEW! |
FORMULATION DEVELOPMENT OF siRNAs FOR DRUG DELIVERY: A NEW THERAPEUTIC APPROACH FOR PANDEMIC INFLUENZA.
Prieve, M.G., Ge, Q., Lamharzi, N., Cui, K., Thomson, A., Thompson, S., Templin, M., Wang, H., Farber, K., Roth, S., Houston, M., Johnson, P.H.
Nastech Pharmaceutical Company, Inc., Bothell, Washington.
Presented at the American Association of Pharmaceutical Sciences (AAPS) Biotechnology Conference, Boston, MA, June 18-21 (2006).
|
413. |
NEW! |
THERAPEUTIC UTILITY OF A NOVEL TIGHT JUNCTION MODULATING PEPTIDE FOR ENHANCING INTRANASAL DRUG DELIVERY.
Chen, S.C., Eiting, K., Cui, K., Leonard, A.K., Morris, D., Li, C.Y., Farber, K., Sileno, A.P., Houston, M.E., Johnson, P.H., Quay, S.C., Costantino, H.R.
Nastech Pharmaceutical Company, Inc., Bothell, Washington.
Journal of Pharmaceutical Sciences, 95, (6) 1364-1371 (2006).
|
410. |
NEW! |
TH2 CYTOKINE STIMULATED AIRWAY EPITHELIAL CELLS DEMONSTRATE GRANULE-DEPENDENT FasL LOCALIZATION.
Singhera, G.K., Sekhon, M.S., Dorscheid, D.R.
The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, St. Paul’s Hospital / Providence Health Care-University of British Columbia, Vancouver, BC, Canada.
Presented at the American Thoracic Society Annual Meeting, San Diego, CA., May 19-24 (2006).
|
409. |
NEW! |
DRUG/XENOBIOTIC-METABOLIZING ENZYME (XME) EXPRESSION IN THE EPIAIRWAY IN VITRO HUMAN AIRWAY MODEL: UTILITY FOR ASSESSING TRACHEAL/BRONCHIAL BIOTRANSFORMATION OF INHALED PHARMACEUTICALS AND ENVIORNMENTAL CHEMICALS.
Hayden, P.J., Bolarcich, J., Stopler, G., Jackson, G.R., Klausner, M.
MatTek Corporation, Ashland, MA, USA.
Presented at the American Thoracic Society 2006 Annual Meeting, San Diego CA, May 19-24 (2006).
|
396. |
NEW! |
LONG-TERM BIOLOGICAL BYSTANDER EFFECTS OF MICROBEAM IRRADIATION IN 3D HUMAN TISSUE MODELS.
Sedelnikova1, O.A., Nakamura1, A., Koturbash2, I., Kovalchuk3, O., Mitchell3, S.A., Marino3, S.A., Brenner3, D.J., Bonner1, W.M.
1Laboratory for Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD; 2Department of Biological Sciences, University of Lethbridge, Lethbridge, AB, Canada; 3Radiation Accelerator Research Facility, Center for Radiological Research, Columbia University, College of Physicians and Surgeons, New York, NY.
Poster presented at the 7th International Workshop on Microbeam Probes, New York, NY, March 15-17, (2006).
|
394. |
NEW! |
LONG TERM CULTURE OF PSEUDOSTRATIFIED TRACHEAL BRONCHIAL EPIAIRWAY™ TISSUES.
Hayden, P., Jackson, G.R.
MatTek Corporation, Ashland, MA, United States.
Internal results, (2006).
|
391. |
NEW! |
PEPTIDE DRUG PERMEATION ENHANCEMENT BY SELECT CLASSES OF LIPIDS.
Chen, S-C., Eiting, K.T., Li1, A.A.W., Lamharzi, N. and Quay, S.C.
Nastech Pharmaceutical Company Inc. 3450 Monte Villa Parkway, Bothell, WA 98021, USA. 1Bioengineering, University of Washington.
Presented at the 45th American Society of Cell Biology, San Francisco, CA, December 10-14, (2005).
|
390. |
NEW! |
DEVELOPMENT OF A NOVEL HIGH-CONCENTRATION GALANTAMINE FORMULATION SUITABLE FOR INTRANASAL DELIVERY.
Leonard, A.K., Sileno, A.P., MacEvilly, C., Foerder, C.A., Quay, S.C., and Costantino, H.R.
Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell, WA 98021.
Journal of Pharmaceutical Sciences, 94, 1736-1746, (2005).
|
384. |
NEW! |
IN VITRO ALTERNATIVES IN INHALATION TOXICOLOGY - WHERE DO WE START?
Greenwell1, L., Roggen2, E., Holder3, J., Westmoreland1, C., Cathew1, P., Fentem1, J.
1Safety and Environment Assurance Centre, Unilever Colworth, Sharnbrook, Bedford, U.K., 2Novozyme A/S, Smoermoseve, Bagsvaerd, Denmark, 3Glaxo-Smith-Kline, Ware, Hertfordshire, U.K.
Presented at the 5th World Congress, Berlin, Germany, August 21-25, (2005).
|
383. |
NEW! |
MODELLING THE HUMAN BRONCHI AND ITS RESPONSES IN VITRO.
Greenwell, L., Carthew, P., Westmoreland, C., and Fentem, J.
Safety and Enviornmental Assurance Centre, Unilever Colworth, Sharnobrook, Bedford, U.K.
Presented at 5th World Congress, Berlin, Germany, August, (2005).
|
370. |
|
MICROARRAY EXPRESSION STUDIES ON AN IN VITRO MODEL OF HUMAN AIRWAY EPITHELIUM (EPIAIRWAY™).
Moffatt1, M.F., Hill1, A.L., Hao1, L., Taylor2, J., Hayden3, P.J., Cookson1, W.O.C.M.
1Wellcome Trust Centre for Human Genetics, University of Oxford, U.K; 2Department of Statistics, Oxford Centre for Gene Function, University of Oxford, U.K; 3MatTek Corporation, Ashland, MA, U.S.A.
Presented at American Thoracic Society, San Diego, CA, May 20-25, (2005).
|
368. |
|
INTRANASAL DELIVERY OF RECOMBINANT HUMAN PARATHYROID HORMONE [HPTH (1–34)], TERIPARATIDE IN RATS.
Agu1, R.U., Valiveti1, S., Earles1, D.C., Klausner2, M., Hayden2, P.J., Wermeling1,3,D.P., Stinchcomb1, A.L.
1College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA; 2MatTek Corporation, Ashland, Massachusetts, USA; 3Intranasal Technology, Inc., Lexington, Kentucky, USA.
Endocrine Research, 30, (3), 455-467, (2004).
|
359. |
|
IDENTIFICATION OF INTELLIGENT BIOMARKERS OF EXPOSURE AND HARM IN THE RESPIRATORY EPITHELIAL TO TOBACCO SMOKE COMPONENTS.
BéruBé, K., Sexton, K., Jones, T.
School of Biosciences, Cardiff University, Museum Avenue, Cardiff, CF10 3US, Wales, UK.
|
351. |
|
A HIGH-THROUGHPUT IN VITRO MODEL OF HUMAN TRACHEAL/ BRONCHIAL EPITHELIUM (EPIAIRWAY™) FOR PRE-CLINICAL SAFETY AND EFFICACY TESTING OF PHARMACEUTICALS.
Hayden, P.J., Jackson, G., Kubilus, J., Sheasgreen, J., Klausner, M.
MatTek Corporation, Ashland, MA.
Presented at Society of Toxicology Annual Meeting, New Orleans, LA, March 6-10, 2005. The Toxicologist, 84, (1), Abstract # 1171, 240, (2005).
|
347. |
|
THE USE OF FLUORESCENTLY LABELED NANOPARTICLES TO DETERMINE THE EFFECT OF PARTICLE SIZE ON TRANSLOCATION FROM THE LUNG.
Carter1, J.M., Kennedy1, J.M., Oberdorster2, G., Clark3, E.D.
1The Procter & Gamble Co., Cincinnati, OH; 2University of Rochester, Rochester, NY; 3The Health and Environmental Safety Alliance, Cincinnati, OH.
Presented at Society of Toxicology Annual Meeting, Baltimore, MD. March 21-25, (2004).
|
345. |
|
LOCALIZATION OF P-GLYCOPROTEIN IN HYMAN TRACHEAL/BRONCHIAL EPITHELIAL CELL CULTURE (EPIAIRWAY™).
Chemuturi1, N., Hayden2, P., Klausner2, M., Donovan1, M.
1Division of Pharmaceutics, The University of Iowa, Iowa City, IA; 2MatTek Corporation, Ashland, MA.
Presented at American Association of Pharmaceutical Scientists Annual Meeting, Baltimore, MD. November 7-10, (2004).
|
344. |
|
CANNABIDIOL DIFFUSION ACROSS HUMAN TRACHEO-BRONCHIAL TISSUE (EPIAIRWAY™) AND INTRANASAL ABSORPTION IN RATS.
Agu1, R., Valiveti1, S., Paudel1, K., and Klausner2, M., Hayden2, P.
University of Kentucky College of Pharmacy, Lexington, KY; 2MatTek Corporation, Ashland, MA.
Presented at American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, Baltimore, MD. November 7-10, (2004).
|
332. |
|
AN IN VITRO MODEL OF FULL-THICKNESS HUMAN AIRWAY EPITHELIUM (EPIAIRWAY-FT™) FOR STUDY OF EPITHELIUM/MATRIX INTERACTIONS.
Hayden, P. J., Klausner, M., Kubilus, J., Burnham, B., Jackson, G. R.
MatTek Corporation, Ashland, MA.
Presented at the American Thoratic Society Meeting, Orlando, FL, May 21-26, (2004).
|
331. |
|
PERMEATION OF WIN 55,212-2, A POTENT CANNABINOID RECEPTOR AGONIST, ACROSS HUMAN TRACHEO-BRONCHIAL TISSUE (EPIAIRWAY™) IN VITRO AND RAT NASAL EPITHELIUM IN VIVO.
Agu1, R.U., Valiveti1, S., Paudel1, K.S., Klausner2, M., Hayden2, P.J., Stinchcomb1, A.S.
1University of Kentucky College of Pharmacy, Lexington, KY, 2MatTek Corporation, Ashland, MA.
Journal of Pharmacy and Pharmacology, 58, 1-7, (2006).
|
315. |
|
DRUG PERMEABILITY ACROSS BOVINE RESPIRATORY TISSUES COMPARED TO A HUMAN TRACHEO/BRONCHIAL CELL CULTURE (EPIAIRWAY™ SYSTEM).
Chemuturi1, N., Donovan1, M., Klausner2, M., and Hayden2, P.
1College of Pharmacy, University of Iowa, Iowa City, IA. 2MatTek Corporation, Ashland, MA.
Poster presented at the American Association of Pharmaceutical Scientists (AAPS), Salt Lake City, UT, October 26-30, (2003).
|
314. |
|
DOPAMINE TRANSPORT ACROSS RESPIRATORY EPITHELIUM.
Chemuturi1, N., Donovan1, M., Klausner2, M., and Hayden2, P.
1College of Pharmacy, University of Iowa, Iowa City, IA. 2MatTek Corporation, Ashland, MA.
Poster presented at the American Association of Pharmaceutical Scientists (AAPS), Salt Lake City, UT, October 26-30, (2003).
|
310. |
|
DEVELOPMENT OF AN INTRANASAL FORMULATION OF THE Y2R AGONIST PEPTIDE YY3-36.
Kleppe, M., Deshpande, A., Go, Z., Constantino, H.R., Sileno, A., Brandt, G., Lee*, M., Quay, S.
Nastech Pharmaceuticals, Bothell, WA and *UCLA, Los Angeles, CA.
|
304. |
|
STUDIES OF BYSTANDER EFFECTS IN ARTIFICIAL HUMAN 3D TISSUE SYSTEMS USING A MICROBEAM IRRADIATION.
Belyakov, O.V., Hall, E.J., Marino, S.A., Randers-Pehrson, G., Brenner, D.J.
Columbia University, Irvington, NY. Center for Radiological Research
(Annual Report), (2002).
|
300. |
|
IN VITRO MODELS OF FULL-THICKNESS HUMAN SKIN (EPIDERMFT™) AND AIRWAY EPITHELIUM (EPIAIRWAYFT™) FOR TOXICOLOGY AND DRUG DEVELOPMENT APPLICATIONS.
P.J. Hayden, M. Klausner, J. Kubilus, B. Burnham and G.R. Jackson.
MatTek Corporation, Ashland, MA 01721.
Presented at the 2003 Congress on In Vitro Biology, Portland, OR (May 31-June 4)
|
298. |
|
REPRODUCIBILITY OF EPIAIRWAY™, A DIFFERENTIATED AIRWAY TISSUE MODEL FOR PRE-CLINICAL DRUG DEVELOPMENT STUDIES.
Patrick J. Hayden, Mitchell Klausner, Joseph Kubilus, Robert Jackson, Elizabeth J. Roemer1.
MatTek Corporation, Ashland, MA 01721, 1State University of New York at Stony Brook, Stony Brook, NY, 11794.
Presented at the American Thoracic Society (ATS) International Conference, Seattle, WA, May 19, 2003.
|
271. |
|
AN IN VITRO MODEL FOR THE RAPID SCREENING OF POTENTIAL COMPONENTS AND FORMULATIONS FOR NASAL DRUG DELIVERY.
Scotto-Lavino, E., Easow, J., Simon, S., and Roemer, E.,
State University of New York (SUNY) at Stony Brook, Stony Brook, NY.
In Vitro Cellular and Developmental Biology, 38, 12A (2002).
|
267. |
|
TUMOR NECROSIS FACTOR ALPHA (TNFα) INDUCTION OF THYMUS AND ACTIVATION REGULATED CHEMOKINE (TARC) EXPRESSION IS MEDIATED BY 15-LIPOXYGENASE 15-(LOX)-2 IN THE EPIAIRWAY™ HUMAN TRACHEAL/BRONCHIAL EPITHELIAL MODEL.
Jackson1, G.R., Last1, T.J., Klausner1, M., Kubilus1, J., Shappell2, S.B., Brash2, A.R. and Hayden1, P.
1MatTek Corporation, Ashland, MA USA, and 2Department of Pathology, Vanderbilt University School of Medicine, Nashville, TN USA.
Presented at the American Thoracic Society Meeting, Atlanta, GA, May (2002).
|
256. |
|
EXPRESSION OF 15-LIPOXYGENASE-2 IN THE EPIAIRWAY™ IN VITRO HUMAN TRACHEAL/BRONCHIAL EPITHELIAL MODEL: REGULATION BY TNF-α AND INF-γ.
Hayden1, P.J., Jackson1, G.R., Last1, T.J., Klausner1, M., Kubilus1, J., Shappell2, S.B.
1MatTek Corp., Ashland, MA, 2Department of Pathology, Vanderbilt University School of Medicine, Nashville, TN.
The Toxicologist, 66 (1-S), 100, Soc. of Toxicol. (Reston, VA), Abstract #486, (2002).
|
244. |
|
EFFECTS OF ENHANCERS ON MACROMOLECULES FORMULATIONS ON MEMBRANE PENETRATION, CELL VIABILITY AND RESISTANCE USING EPIAIRWAY™ TISSUE MODEL.
Quay, S.C., deMeireles, J., Wormuth, D., Vangalla, S., and Biswas, M.
Nastech Pharmaceutical Company, Hauppauge, NY, USA.
AAPSPharmSci, Vol. 3, No. 3, S-57, (2001).
|
243. |
|
PERMEABILITY AND CYTOTOXICITY OF MACROMOLECULE FROM NASAL FORMULATION USING EPIAIRWAY TISSUE MODEL.
El-Shafy, M.A., Roemer, E., deMeireles, J., Biswas, M., Quay, S.C.
Nastech Pharmaceutical Company, Hauppauge, NY, USA.
AAPSPharmSci, Vol. 3, No. 3, S-58, (2001).
|
242. |
|
CHARACTERIZATION OF INFLAMMATORY MEDIATOR RELEASE FROM AN IN VITRO HUMAN TRACHEAL/BRONCHIAL EPITHELIAL TISSUE MODEL.
Hayden, P., Jackson, R., Last, T.J., Klausner, M. and Kubilus, J.
MatTek Corp., Ashland, MA 01721.
The Toxicologist, 60 (1), 425, Soc. of Toxicol. (Reston, VA), Abstract #2023, (2001).
|
225. |
|
CHARACTERIZATION OF INFLAMMATORY MEDIATOR RELEASE FROM AN IN VITRO HUMAN BRONCHIAL/TRACHEAL EPITHELIAL TISSUE MODEL.
Hayden, P., Jackson, R., Klausner, M., Kubilus, J.
MatTek Corp., Ashland, MA.
Presented at the Lovelace Respiratory Research Institute International Symposium, Santa Fe, NM, October 3, (2000).
|
168. |
|
RECONSTRUCTED, DIFFERENTIATED AIRWAY EPITHELIAL CULTURES TO DETECT OCCUPATIONAL ASTHMA CAUSING AGENTS.
Sheasgreen, J., Klausner, M., Kubilus, J., Ogle, P.
MatTek Corp., Ashland, MA. USA.
The Toxicologist, 48 (1-S), 126, Soc. of Toxicology (Reston, VA), Abstract #594, (1999).
|
156. |
|
RECONSTRUCTED, DIFFERENTIATED AIRWAY EPITHELIAL CULTURES TO MODEL RESPIRATORY INFECTION.
Klausner1, M., Kubilus1, J., Ogle1, P., Adamou2, J.E., Langermann2, S.
1MatTek Corp., Ashland, MA 01721, 2MedImmune Incorporated, Gaithersburg, MD 20878.
Presented at the Lovelace Respiratory Research Institute symposium, "Validity of animal models of human respiratory diseases", Santa Fe, NM, October 1, (1998).
|
|
|
